Single Genome Analysis for the Detection of Linked Multiclass Drug Resistance Mutations in HIV-1-Infected Children After Failure of Protease Inhibitor-Based First-Line Therapy.
PMID: 25923117
2015
Journal of acquired immune deficiency syndromes (1999)
Result: Bulk sequence analyses detected baseline NVP-selected resistance in 5 of 10 children: K103N, V106M, and Y188C in 1 child each and Y181C in 2 children.
A post-partum single-dose TDF/FTC tail does not prevent the selection of NNRTI resistance in women receiving pre-partum ZDV and intrapartum single-dose nevirapine to prevent mother-to- child HIV-1 transmission.
Result: (K103N and Y188C, K103N and G190AG, A98G and G190AG and Y188C and V90I).
Result: Fifteen (34%) patients had mutations (viz K103N, Y181C, Y188C, Y188HY, and G190AG) associated with high level resistance to NNRTI, in particular NVP, whilst 1 (2%) patient had K101E associated with intermediate resistance to NNRTIs.
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
Result: Sixteen out of 23 (70%) had NNRTI mutations (Y181C/I/D: 10; K103N: 6; V106A/I: 3; Y188C/L: 2; K101Q/E: 2; M230L: 1; P225H: 1; A98G: 1; V108I: 1; F227L: 1; K238T: 1), and 10 had >1 NNRTI mutation.
Table: Y188C
Comparison of 454 Ultra-Deep Sequencing and Allele-Specific Real-Time PCR with Regard to the Detection of Emerging Drug-Resistant Minor HIV-1 Variants after Antiretroviral Prophylaxis for Vertical Transmission.
Result: Twenty-eight NVP-selected mutations (V90I, K101E, K103N/R, V106A/I/M, V108I, E138A/G/K/R, Y181C, Y188C, G190A or P225H) were detected in 19 samples at levels of 1.1% to 99.1%.
Table: Y188C
HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy.
Figure: Major NNRTI-associated DRMs (HIVDB score >=60) included: L100I, K101P, K103N/S, V106A/M, Y181C/I/V, Y188L/H/C, G190A/S/E/Q, and M230L.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
PMID: 23934770
2014
The Journal of antimicrobial chemotherapy
Abstract: RESULTS: Sixteen mutations at 10 positions were significantly associated with the greatest contribution to reduced phenotypic susceptibility (>=10-fold) to one or more NNRTIs, including: 14 mutations at six positions for nevirapine (K101P, K103N/S, V106A/M, Y181C/I/V, Y188C/L and G190A/E/Q/S); 10 mutations at six positions for efavirenz (L100I, K101P, K103N, V106M, Y188C/L and G190A/E/Q/S); 5 mutations at four positions for etravirine ( PMID: 24969820
2014
The Biochemical journal
Result: Because NNRTIs inhibit the excision activity of RT, we next screened each hit for their capacity to inhibit RTs containing the NNRTI resistance mutations K103N, V106A, V179D, Y181C, Y188C or G190A.
Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV.
Abstract: Four hundred twelve (98%) women had primary endpoint results available; of these, 5 (1.2%) had new NVP resistance detected by population genotype: 4 of 215 in the 7-day arms (1.9%; K103N in 4 women with Y181C, Y188C, or G190A in 3 of 4) and 1 of 197 (0.5%; V108I) in the 21-day arms (P = .37).
Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data.
Result: Another interesting observation is that mutations Y188C and G190A are predicted to render HIV more sensitive to Etravirine according to our model.
HIV mutation literature information.
PMID: 
2015
Journal of acquired immune deficiency syndromes (1999)
Browser Board
Co-occurred Entities
Filtrator
ViMRT